MX2022014741A - Metodos para detectar bordetella. - Google Patents

Metodos para detectar bordetella.

Info

Publication number
MX2022014741A
MX2022014741A MX2022014741A MX2022014741A MX2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A MX 2022014741 A MX2022014741 A MX 2022014741A
Authority
MX
Mexico
Prior art keywords
bordetella
methods
detecting
pertussis
holmesii
Prior art date
Application number
MX2022014741A
Other languages
English (en)
Inventor
Michelle Tabb
Jules Chen
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2022014741A publication Critical patent/MX2022014741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente descripción proporciona métodos para determinar si un paciente que exhibe síntomas similares a la tos ferina se beneficiará a partir del tratamiento con agentes terapéuticos que inhiban Bordetella holmesii. Estos métodos se basan en la detección de Bordetella pertussis, Bordetella parapertussis y Bordetella holmesii en una muestra biológica por medio del ensayo para determinar la presencia de los elementos de repetición objetivo de IS481, IS1001 y hIS1001, respectivamente. También se proporcionan los kits para utilizarse en la práctica de los métodos.
MX2022014741A 2016-03-24 2018-09-24 Metodos para detectar bordetella. MX2022014741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312883P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
MX2022014741A true MX2022014741A (es) 2023-01-11

Family

ID=59899804

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011625A MX2018011625A (es) 2016-03-24 2017-03-23 Metodos para detectar bordetella.
MX2022014741A MX2022014741A (es) 2016-03-24 2018-09-24 Metodos para detectar bordetella.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011625A MX2018011625A (es) 2016-03-24 2017-03-23 Metodos para detectar bordetella.

Country Status (7)

Country Link
US (1) US20190382826A1 (es)
EP (2) EP4144867A1 (es)
CN (1) CN109153699A (es)
BR (1) BR112018069316A2 (es)
CA (1) CA3018843A1 (es)
MX (2) MX2018011625A (es)
WO (1) WO2017165599A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11215573B2 (en) * 2016-01-14 2022-01-04 Jamlet MONASELIDZE Differential scanning microcalorimeter device for detecting disease and monitoring therapeutic efficacy
EP3856934A2 (en) * 2018-09-27 2021-08-04 Gen-Probe Incorporated COMPOSITIONS AND METHODS FOR DETECTING BORDETELLA PERTUSSIS AND BORDETELLA
PARAPERTUSSIS NUCLEIC ACID
AU2020210983B2 (en) * 2019-01-23 2024-05-16 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
CN110468223B (zh) * 2019-09-26 2020-07-31 北京卓诚惠生生物科技股份有限公司 基于dUTP/UNG法的肺炎支原体和鲍特菌属核酸检测的引物、探针、试剂盒及方法
CN113373143A (zh) * 2021-07-13 2021-09-10 国药(武汉)医学实验室有限公司 一种用于副百日咳鲍特菌检测探针、试剂盒及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254062A1 (en) * 2007-02-23 2008-10-16 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
US10465252B2 (en) * 2007-10-26 2019-11-05 Quest Diagnostics Investments Incorporated Bordetella detection assay
WO2010124281A2 (en) * 2009-04-24 2010-10-28 The Goverment Of The Usa, As Represented By The Secretary, Department Of Health And Human Services,Centres For Disease Control And Prevention Selective detection of bordetella species
BR112014000138B1 (pt) * 2011-07-06 2021-11-16 Quest Diagnostics Investments Incorporation Método para identificar a presença ou ausência de um ácido nucleico alvo
JP6254085B2 (ja) * 2011-10-04 2017-12-27 ジェネラ バイオシステムズ リミテッド 核酸プローブ及びビーズサブセットを用いて呼吸器病原体を検出する組成物及び方法
WO2015066530A1 (en) * 2013-10-31 2015-05-07 Atherotech, Inc. Methods for nucleic acid amplification
EP3224383B1 (en) * 2014-11-25 2020-02-12 Quest Diagnostics Investments Incorporated Amplification and detection of nucleic acids in a biological sample

Also Published As

Publication number Publication date
MX2018011625A (es) 2019-01-10
EP3442984A4 (en) 2019-11-06
BR112018069316A2 (pt) 2019-01-22
CA3018843A1 (en) 2017-09-28
WO2017165599A1 (en) 2017-09-28
CN109153699A (zh) 2019-01-04
EP3442984A1 (en) 2019-02-20
US20190382826A1 (en) 2019-12-19
EP4144867A1 (en) 2023-03-08
EP3442984B1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
MX2022014741A (es) Metodos para detectar bordetella.
EA201790716A1 (ru) Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
MX2022014633A (es) Metodos para detectar norovirus.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
BR112016020053A2 (pt) métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
MX2019005443A (es) Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
BR112016019740A2 (pt) monitoramento do estado de inflamação
MX2019007894A (es) Composiciones y metodos para detectar el adn tumoral circulante.
EP4268820A3 (en) Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
GB2552271A (en) A method for diagnosing lung cancer
EP1899726A4 (en) METHODS FOR DIAGNOSING AND TREATING CEREBROVASCULAR EVENTS BASED ON NR2 PEPTIDES
EA202192289A1 (ru) Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений
MX2021009281A (es) Metodos de deteccion de legionella.
ES2530866T3 (es) Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
WO2015126922A3 (en) Rapid phenotype tests for antitubercular drug sensitivity and resistance
EA201691393A1 (ru) Методы анализа клиренса субстрата для лизосомальных ферментов
Fakhri et al. Measuring Cardiopulmonary Complications of Carfilzomib Treatment and Associated Risk Factors Using the SEER-Medicare Database
WO2014110230A3 (en) Methods for diagnosing cancer based on small nucleolar rna hbii-52